Deverra: Phase 1:DVX201 NK cells in R/R AML High risk MDS or Myeloproliferative Neoplasms

Clinical Trial Grant

Duke Scholars

Principal Investigator Thomas William LeBlanc Medicine, Hematologic Malignancies and Cellular Therapy

Awarded By

Deverra Therapeutics

Start Date

November 3, 2021

End Date

November 14, 2026

Awarded By

Deverra Therapeutics

Start Date

November 3, 2021

End Date

November 14, 2026